Neurona Therapeutics Reveals Three Leadership Promotions
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Neurona Therapeutics Reveals Three Leadership Promotions

Pharma Tech Outlook | Friday, December 17, 2021

Neurona Therapeutics makes three promotions within its leadership team to move to the next chapter of Neurona’s evolution.

Fremont, CA: "I am delighted to be able to promote Catherine, Gautam, and David into these newly created roles, and I look forward to their continued contributions towards our success. Together, with our talented team, we are excited to move to the next chapter of Neurona's evolution, bringing the company's pioneering cell therapies to people suffering from chronic disorders of the nervous system," comments Cory Nicholas, Ph.D., Neurona’sPresident, and Chief Executive Officer. Neurona Therapeutics, a clinical-stage biotherapeutics firm developing restorative brain cell therapies to treat chronic neurological illnesses, has revealed three executive promotions: Catherine Priest, Ph.D., formerly of Neurona’sVice President of Preclinical Development, has been named Chief Development Officer,GautamBanik, Ph.D., formerly of Neurona’sVice President of Manufacturing And Process Sciences, has been named Chief Technology Officer, and David Blum, M.D., formerly of Neurona’sHead of Clinical Development, has been named Chief Medical Officer.

“These promotions recognize the strategic leadership that these highly experienced executives have demonstrated in steering the organization through significant research and development progress and milestones,” adds Cory Nicholas. “Advancing NRTX-1001, the first of our innovative regenerative neural cell therapies, into the clinic is the culmination of an enormous amount of hard work by the Neurona team and a testament to the leadership of these three individuals.”

Dr. Nicholas continues, “Dr. Priest led the investigational new drug (IND)-enabling work required to generate compelling preclinical safety and efficacy data for NRTX-1001, applying her significant experience in the translational development of stem cell-based medicines, relevant model systems, and regulatory guidelines. Dr. Banik’s extensive experience in process development and clinical manufacturing of stem cell products has been key to the development of Neurona’s manufacturing processes and production of NRTX-1001 clinical lots in the company’s own cGMP facility. Dr. Blum, a neurologist by training, is also a seasoned pharmaceutical executive who has secured drug approvals in the U.S., Canada and Europe and designed the first-in human clinical trial of NRTX-1001 for chronic focal epilepsy.”

Weekly Brief

Read Also